Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Polyclonal antibodies against gp185(HER2) peptides: Their putative role inthe identification of a particular HER2 status in patients with breast cancer
Autore:
Di Modugno, F; Buglioni, S; Mottolese, M; Del Bello, D; Cascioli, S; Chersi, A; Santoni, A; Nistico, P;
Indirizzi:
CRS Ist Tumori Regina Elena, Lab Pathophysiol, I-00158 Rome, Italy CRS IstTumori Regina Elena Rome Italy I-00158 siol, I-00158 Rome, Italy Regina Elena Canc Inst, Pathol Lab, Rome, Italy Regina Elena Canc Inst Rome Italy na Canc Inst, Pathol Lab, Rome, Italy CRS Regina Elena Canc Inst, Biochem Lab, Rome, Italy CRS Regina Elena CancInst Rome Italy nc Inst, Biochem Lab, Rome, Italy Univ Rome La Sapienza, Dept Expt Med & Pathol, Rome, Italy Univ Rome La Sapienza Rome Italy a, Dept Expt Med & Pathol, Rome, Italy
Titolo Testata:
JOURNAL OF IMMUNOTHERAPY
fascicolo: 3, volume: 24, anno: 2001,
pagine: 221 - 231
SICI:
1524-9557(200105/06)24:3<221:PAAGPT>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
EPIDERMAL GROWTH-FACTOR; CLASS-I; EXTRACELLULAR DOMAIN; HER-2/NEU PROTEIN; IMMUNE-RESPONSES; OVARIAN-CANCER; T-CELL; OVEREXPRESSION; CONTRIBUTES; ONCOGENE;
Keywords:
HER2 status; antipeptide antibodies; HLA-A2; breast cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Nistico, P CRS Ist Tumori Regina Elena, Lab Pathophysiol, Via Messi Oro 156, I-00158 Rome, Italy CRS Ist Tumori Regina Elena Via Messi Oro 156 Rome Italy I-00158
Citazione:
F. Di Modugno et al., "Polyclonal antibodies against gp185(HER2) peptides: Their putative role inthe identification of a particular HER2 status in patients with breast cancer", J IMMUNOTH, 24(3), 2001, pp. 221-231

Abstract

The HER2 oncogene and its relative oncoprotein, gp185(HER2), a transmembrane glycoprotein belonging to the epidermal growth factor receptor family, are overexpressed in a wide range of solid tumors including breast and ovarian cancer. In patients with breast cancer, both humoral and cell-mediated HER2 immune responses have been found as well as in some patients with gp185(HER2) nonoverexpressing tumors. To establish whether peptide sequences identified as HLA-A2-restricted T-cell epitopes are expressed in breast tumor cell lines and tissues, we produced and characterized by different methodologic approaches polyclonal antibodies raised against four gp185(HER2) peptides. Two of the antibodies recognized peptides eluted from the HLA-A2 groove of the mDAmB231 breast cancer cell line expressing a basal level of gp185(HER2). Paraffin-embedded primary and metastatic breast tumors were specifically immunostained by all four reagents, thereby showing an overlapping reactivity. When this immunoreactivity was compared with that obtained using two different monoclonal antibodies, in 105 breast primary tumors and 36 corresponding lymph node metastases, we identified a subset of tumors that were negative with anti-gp185(HER2) monoclonal antibodies and positive with the four antipeptide antibodies. Our novel observations provide in vivo evidence of the complexity involved in evaluating HER2 expression, and open a new path for understanding the biologic significance of HER2 status in breast tumors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/08/20 alle ore 02:33:33